Aviso Wealth Management’s Biogen BIIB Stock Holding History

Aviso Wealth Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,425	Closed	-$369K	–	152
2023 Q4	$369K	Buy	+1,425	New	+$350K	0.27%	91

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Aviso Wealth Management's BIIB Position: Q1 2024 in Review

Aviso Wealth Management sold out of Biogen (BIIB) in Q1 2024, closing a stake of 1,425 shares — an estimated $369K sold.

Aviso Wealth Management first reported a position in BIIB in Q4 2023 and held it in 1 quarter. The position peaked at $369K in Q4 2023. 955 funds tracked by Wall St. Rank hold BIIB as of Q1 2024.

Aviso Wealth Management reported no remaining Biogen position as of Q1 2024 after selling out during the quarter.
Aviso Wealth Management sold 1,425 Biogen shares in Q1 2024, an estimated $369K.
Aviso Wealth Management first reported a position in Biogen in Q4 2023 and held it in 1 quarter.
Aviso Wealth Management's Biogen position peaked at $369K in Q4 2023.
955 funds tracked by Wall St. Rank held Biogen as of Q1 2024.

Based on Aviso Wealth Management's 13F filing for Q1 2024, filed 14 May 2024.